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Summary
Impaired T helper type 1 (Th1) function is implicated in the susceptibility
of patients with chronic obstructive pulmonary disease (COPD) to respi-
ratory infections, which are common causes of acute exacerbations of
COPD (AECOPD). To understand the underlying mechanisms, we
assessed regulatory T (Treg) cells and the expression of an inhibitory T-
cell receptor, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Cry-
opreserved peripheral blood mononuclear cells (PBMC) from patients
with AECOPD (n = 17), patients with stable COPD (sCOPD; n = 24) and
age-matched healthy non-smoking controls (n = 26) were cultured for
24 hr with brefeldin-A or monensin to detect intracellular or surface
CTLA-4 (respectively) by flow cytometry. T cells in PBMC from AECOPD
(n = 9), sCOPD (n = 14) and controls (n = 12) were stimulated with
anti-CD3 with and without anti-CTLA-4 blocking antibodies and cytoki-
nes were quantified by ELISA. Frequencies of circulating T cells express-
ing intracellular CTLA-4 were higher in sCOPD (P = 001), whereas
patients with AECOPD had more T cells expressing surface CTLA-4 than
healthy controls (P = 003). Increased frequencies of surface CTLA-
4+ CD4+ T cells and CTLA-4+ Treg cells paralleled increases in plasma
soluble tumour necrosis factor receptor-1 levels (r = 032, P = 001 and
r = 029, P = 002, respectively) in all subjects. Interferon-c responses to
anti-CD3 stimulation were inversely proportional to frequencies of CD4+
T cells expressing intracellular CTLA-4 (r = 043, P = 001). Moreover,
CTLA-4 blockade increased the induction of interferon-c, tumour necrosis
factor-a and interleukin-6 in PBMC stimulated with anti-CD3. Overall,
chronic inflammation may expand sub-populations of T cells expressing
CTLA-4 in COPD patients and therefore impair T-cell function. CTLA-4
blockade may restore Th1 function in patients with COPD and so aid the
clearance of bacterial pathogens responsible for AECOPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is one of
the top five causes of morbidity and mortality worldwide.
Smoking is the most common cause of COPD, but genetic
factors and environmental pollutions are also implicated.1
The disease is characterized by progressive limitation of
airflow, with abnormal inflammatory responses to inhaled
particles or gases.2 The chronic inflammation of the
airways involves infiltration and activation of neutrophils,
macrophages and T cells.3–5 Subsequent systemic inflam-
mation contributes to co-morbidities (e.g. cardiovascular
disease and cachexia).6
Most patients are relatively stable with treatment
(sCOPD), but some experience acute exacerbations of
COPD (AECOPD), which increase mortality and morbid-
ity.7 AECOPD is defined as ‘an event in the natural
course of the disease characterized by a change in the
patient’s baseline dyspnoea, cough and/or sputum, and
beyond normal day-to-day variations, that is acute in
onset and may warrant a change in regular medication in
a patient with underlying COPD’.2 Respiratory bacterial
infections account for up to 50% of AECOPD events.
Non-typeable Haemophilus influenzae (NTHI), Streptococ-
cus pneumoniae and Moraxella catarrhalis are the major
bacterial pathogens isolated from patients with
AECOPD.8 As NTHI oral vaccines do not reduce the fre-
quency and severity of AECOPD,9 the capacity to mount
a protective anti-bacterial immune response may be lim-
ited in patients with COPD.
Despite its inflammatory aetiology, COPD is considered
as an immune-deficient state as the abundant activated T
cells in the airways of COPD patients do not eradicate
bacterial infections. Indeed, T helper type 1 (Th1)
immune responses [e.g. production of interferon-c (IFN-
c) and phagocytosis] are impaired in patients with
COPD.10–13 Exogenous IFN-c can enhance killing of
NTHI by monocytes from patients with bronchiectasis,14
confirming the necessity for appropriate Th1 responses
for clearance of bacterial infections. Here we address the
regulators of T-cell responses in patients with COPD and
search for means to improve host production of IFN-c.
An important regulator of T-cell function is cytotoxic
T-lymphocyte antigen-4 (CTLA-4), which blocks the
CD28-mediated activation of T cells.15 CTLA-4 is consti-
tutively expressed by regulatory T (Treg) cells and acti-
vated effector T cells. It inhibits the proliferation of T
cells and the production of pro-inflammatory cytokines,
and so prevents continuous T-cell activation.15,16 Poly-
morphisms in the gene encoding CTLA-4 (e.g. rs231775
and rs5742909) and increased serum levels of the soluble
form of CTLA-4 have been associated with dysregulated
T-cell responses and increased susceptibility to COPD
and chronic bronchitis.17–20 Furthermore, increased levels
of soluble CTLA-4 in the serum of patients with COPD
paralleled decreased lung function and increased C-reac-
tive protein (CRP).21 Frequencies of circulating CTLA-4+
T cells and CTLA-4+ Treg cells were also higher in
patients with COPD than in controls.22,23 Kalathil et al.
reported that CTLA-4 blockade in vitro increased the pro-
liferation of CD4+ and CD8+ T cells and production of
IFN-c by peripheral blood mononuclear cells (PBMC)
from three patients with COPD.24
Here in a larger patient cohort, we address the possibil-
ity that chronic inflammation in patients with COPD
may increase CTLA-4 expression or proportions of Treg
cells which constitutively express CTLA-4, so limiting
protective Th1-cell responses (e.g. IFN-c production). Lit-
tle is known about the role of CTLA-4 in AECOPD in
terms of levels of expression and anti-bacterial function.
Furthermore, most studies have only assessed intracellular
expression as surface expression is complicated by the
rapid endocytosis of CTLA-4. Hence we have addressed
the expression of intracellular and surface CTLA-4 using
novel assays and hypothesized that the expression of
CTLA-4 is elevated in AECOPD, which reduces antibacte-
rial responses such as IFN-c production.
Methods
Study subjects and sample collection
Patients with AECOPD (n = 17; 7 current smokers and
10 ex-smokers) were recruited on admission to the Emer-
gency Department in Royal Perth Hospital in Western
Australia. Patients with stable COPD (sCOPD; n = 24, all
ex-smokers) were recruited from a dedicated COPD clinic
at Royal Perth Hospital. All AECOPD and sCOPD
patients had a smoking history of > 15 pack-years and
ex-smokers were defined as those who had ceased smok-
ing > 1 year earlier. The diagnosis and severity of COPD
was established by a respiratory physician according to
the GOLD criteria (Stages 2–4).25 All patients with COPD
had been treated with anticholinergic drugs, long-acting
beta agonists and inhaled corticosteroids for >3 months
before participating in the study. Co-morbidities included
hypertension, osteoporosis and ischaemic heart disease.
No patients were receiving systemic corticosteroids or
had diabetes, neuromuscular, allergic or rheumatological
disease. Age-matched healthy non-smoking controls with
no clinical evidence of COPD and not taking any antibi-
otics or anti-inflammatory medications were tested in
parallel (HC; n = 26). This study was approved by the
Royal Perth Hospital Human Research Ethics Committee
(EC2012/23) and all participants gave informed consent.
Blood samples were collected in lithium heparin tubes,
centrifuged at 1000 g for 10 min and plasma was stored
in aliquots at 80°. PBMC were isolated by Ficoll-Paque
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PLUS density gradient centrifugation (GE Healthcare,
Uppsala, Sweden) and cryopreserved in 10% DMSO/fetal
calf serum (FCS; Gibco by Invitrogen, Carlsbad, CA).
T-cell subsets
The PBMC (1 9 106 cells/ml) were cultured at 37° in 5%
CO2 for 24 hr in polypropylene tubes on a 5-degree
incline in 10% FCS/RPMI. BD GolgiPlugTM (Brefeldin-A
1 lg/ml) or BD GolgiStopTM (monensin; 2 lM) plus
CTLA-4-allophycocyanin (APC) antibodies (BD Bio-
sciences, San Jose, CA) was added after 2 hr. Brefeldin-A
prevents secretion of proteins including CTLA-4 and
hence measures intracellular CTLA-4. As surface expres-
sion of CTLA-4 is transient due to rapid endocytosis,
PBMC were cultured in the presence of CTLA-4-APC
antibodies plus monensin (which prevents acidification
and subsequent degradation of endocytosed CTLA-4 anti-
body complexes) before staining for immunophenotypic
markers. Cells were washed and stained with the BD
HorizonTM Fixable Viability Stain 450, followed by
surface-staining with CD3-APC-H7, CD4-V500, CD8-
Peridinin chlorophyll protein-Cy5.5 and CD45RA-
phycoerythrin-Cy7 antibodies. Intracytoplasmic staining
was done using the BD PharmingenTM Human Foxp3 buf-
fer sets with Foxp3-phycoerythrin and CTLA-4-APC anti-
bodies (BD Biosciences). A total of 200 000 events were
acquired using a BD FACSCanto II cytometer and anal-
ysed with FLOWJO v572 software (Tree Star, Ashland,
OR). The expression of intracellular or surface CTLA-4
was measured in Treg cells (CD25+ Foxp3+ CD4+ CD3+
lymphocytes), total CD4+ T cells (CD4+ CD3+ lympho-
cytes) or total CD8+ T cells (CD8+ CD3+ lymphocytes).
Gating strategies are shown in the Supplementary mate-
rial (Fig. S1).
CTLA-4 blocking assay
The PBMC (2 9 105 cells/well at 1 9 106 cells/ml) from
nine patients with AECOPD, 14 patients with sCOPD
and 12 controls were stimulated with 10 ng/ml anti-CD3
(Mabtech, Nacka Strand, Sweden), with or without
10 lg/ml anti-CTLA-4 antibody (clone BNI3; BD Bio-
sciences) for 24 hr in 96-well flat-bottom plates. Culture
supernatants were stored at 80°C. To measure T-cell
production of IFN-c or tumour necrosis factor-a (TNF-
a), PBMC (1 9 106 cells/ml) from six participants
(AECOPD, n = 2; sCOPD, n = 2; controls, n = 2) were
cultured with 10 ng/ml anti-CD3 for 24 hr, with or with-
out 10 lg/ml anti-CTLA-4 antibody. Brefeldin-A was
added 2 hr after the start of culture. Cells were washed
and stained with the BD HorizonTM Fixable Viability Stain
450, followed by surface-staining with CD3-V500, CD4-
PerCP and CD8-APC-H7 antibodies (BD Biosciences).
Intracytoplasmic staining was performed using the BD
Cytofix CytopermTM buffer sets, IFN-c-BV421 and TNF-a-
phycoerythrin antibodies (BD Biosciences). In all,
200 000 events were acquired using a BD FACSCanto II
cytometer and analysed with FLOWJO v572 software (Tree
Star).
Quantification of soluble biomarkers
Plasma levels of CRP and soluble TNF receptor-1
(sTNFR1) were measured by ELISA (R&D Systems, Min-
neapolis, MN). Concentrations of IFN-c, interleukin-6
(IL-6), IL-10 and TNF-a (BD Biosciences) were measured
in culture supernatants by ELISA with the diluent (10%
FCS/PBS) as a negative control. A sample with known
cytokine concentrations (QC) was assayed on each plate
to assess inter-plate variation (coefficient of variance was
< 10%).
Data analysis
Non-parametric Mann–Whitney U-tests were used to com-
pare data between groups. Wilcoxon matched-pairs signed
rank tests were used to compare data within groups (e.g.
with and without CTLA-4 blocking). Correlations were
assessed using Spearman’s rank correlation coefficients. All
analyses were performed with GRAPHPAD PRISM 504 software
(GraphdPad Software, La Jolla, CA). Statistically significant
differences (P < 005) are indicated in the figures.
Results
Systemic inflammation in patients with AECOPD is
higher than in sCOPD patients
Study demographics are presented in Table 1. Relative to
healthy controls, AECOPD and sCOPD patients exhibited
increased systemic inflammation as defined by higher
levels of plasma CRP (P < 0001 for both) and sTNFR1
(P = 0007 and P < 0001, respectively). Levels of CRP
and sTNFR1 were also higher in patients with AECOPD
than in sCOPD (P = 002 and P = 004, respectively;
Table 1).
Patients with AECOPD exhibit higher frequencies of
circulating Treg cells and CTLA-4+ T cells
The frequency of Treg cells (CD4+ CD25+ Foxp3+) was
higher in patients with AECOPD than in sCOPD
(P = 001) or healthy controls (P = 0001), but similar in
patients with sCOPD and controls (Fig. 1a). Frequencies
of total and memory (CD45RAneg) CD4+ and CD8+ T
cells were similar in all groups (data not shown). The fre-
quency of Treg cells expressing intracellular CTLA-4 was
higher in patients with sCOPD than in controls
(P = 001; Fig. 1b) and correlated with plasma levels of
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sTNFR1 (r = 026, P = 004). The frequency of CD4+ T
cells expressing intracellular CTLA-4 was marginally
higher in patients with sCOPD than controls (P = 006;
Fig. 1c). Expression of intracellular CTLA-4 was low in
CD8+ T cells (< 5%) and did not differ between groups
(Fig. 1d).
Interestingly, the frequency of surface CTLA-4+ Treg
cells or CD4+ T cells are significantly lower than the fre-
quency of intracellular CTLA-4+ Treg cells or CD4+ T
cells, respectively (P < 00001; Fig. 1b versus 1e and
Fig. 1c versus 1f, respectively). The median frequency of
surface CTLA-4+ Treg cells was higher in patients with
AECOPD than in patients with sCOPD (P = 015) or
controls (P = 017), but the difference was not significant
(Fig. 1e). Patients with AECOPD had a higher frequency
of CD4+ T cells with surface CTLA-4+ than controls
(P = 003), but there was no increase in patients with
sCOPD (Fig. 1f). Levels of sTNFR1 correlated with the
proportion of surface CTLA-4+ Treg cells (r = 029,
P = 002) and surface CTLA-4+ CD4+ T cells (r = 032,
P = 001). Few CD8+ T cells expressed surface CTLA-4
(< 1%). The proportions of Treg cells, CD4+ T cells or
CD8+ T cells expressing intracellular or surface CTLA-4
did not differ between patients with AECOPD who were
current smokers compared with those who were ex-smo-
kers (P = 067 to P = 100).
Levels of pro-inflammatory cytokines induced by
anti-CD3 were increased by CTLA-4 blockade in all
subjects
Sufficient PBMC were available from nine patients with
AECOPD, 14 patients with sCOPD and 12 healthy con-
trols. PBMC were cultured with anti-CD3 to induce a
pan T-cell response, with or without added anti-CTLA-4
antibody. Levels of IFN-c, TNF-a, IL-6 and IL-10 in
supernatants of PBMC cultured with anti-CD3 only (no
CTLA-4 blockade) were similar in the three groups
(Fig. 2a–d). Overall the production of IFN-c correlated
inversely with the proportions of Treg cells (r = 046,
P = 0004) and intracellular CTLA-4+ CD4+ T cells
(r = 052, P < 0001).
CTLA-4 blockade increased the anti-CD3-induced
IFN-c, TNF-a and IL-6 responses of PBMC from healthy
controls, and patients with sCOPD and AECOPD
(Fig. 2a–c), whereas IL-10 levels were marginally reduced
(P = 010 to P = 032; Fig. 2d). In a pilot study of two
patients with AECOPD, two with sCOPD and two
healthy controls analysed as a group, CTLA-4 blockade
increased the proportions of IFN-c+ or TNF-a+ CD4+
and CD8+ T cells (Fig. 2e). Hence CTLA-4 blockade may
promote production of pro-inflammatory cytokines while
inhibiting the production of IL-10.
Discussion
Acute exacerbations in patients with COPD are com-
monly associated with respiratory infections,8 reflecting
impaired Th1 responses to bacteria.10–13 For example;
in vitro lymphoproliferative responses to NTHI protein
P6 were lower in patients with AECOPD whose sputum
was culture positive for NTHI than in patients with
COPD with no exacerbations attributed to NTHI.12 How-
ever, the underlying mechanisms have not been eluci-
dated. Here, we provide novel data to support a role for
CTLA-4 and Treg cells in limiting protective Th1
responses in patients with AECOPD. Expression of sur-
face (not intracellular) CTLA-4 in patients with AECOPD
was increased and associated with impaired IFN-c
responses. Furthermore, the blockade of CTLA-4
improved production of Th1 cytokines.
Compared with controls, the frequencies of circulating
CD4+ T cells and Treg cells expressing intracellular
CTLA-4 were higher in patients with sCOPD, whereas
Table 1. Plasma biomarkers of systemic inflammation are increased in patients with chronic obstructive pulmonary disease
Healthy controls Stable COPD AECOPD
N 26 24 17
Sex (male:female)1 14:12 13:11 9:8
Age in years2 75 [53–90] 71 [60–89] 78 [53–92]
Plasma CRP (mg/l) 066 [015–68] 84 [015–73]3 33 [22–157]3,5
Plasma sTNFR1 (ng/ml) 052 [035–10] 13 [079–248]4 189 [113–641]3,5
Abbreviations:AECOPD, acute exacerbation of COPD; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; sTNFR1, soluble
tumour necrosis factor receptor-1.
Data are presented as median [range].
1Similar in all groups (Fisher’s test, P > 005).
2Similar in all groups (Mann–Whitney U-tests, P > 005).
3Higher than controls, P < 0001.
4Higher than controls, P < 001.
5Higher than sCOPD, P < 005.
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patients with AECOPD exhibited increased frequencies of
circulating Treg cells and surface CTLA-4+ CD4+ T cells,
with no significant increase in surface CTLA-4+ Treg cells.
Our data extend previous studies, which have only shown
increased circulating Treg cells in patients with
AECOPD.26 Importantly, we have linked the increased
proportions of CD4+ T cells and Treg cells expressing
surface CTLA-4 with increased levels of plasma sTNFR1.
We suggest that chronic inflammation experienced by all
patients with COPD may expand populations of intracel-
lular CTLA-4+ CD4+ T cells and CTLA-4+ Treg cells. Epi-
sodes of AECOPD may then further activate these cells,
promoting the cycling of CTLA-4 between intracellular
compartments and the cell surface, as shown previously
in PHA-activated PBMC.27 This is the first demonstration
of the critical need to distinguish surface from intracellu-
lar CTLA-4 in patients with AECOPD and patients with
sCOPD.
Splice variants of the CTLA-4 gene may result in the
expression of the transmembrane isoform (Tm-CTLA-4)
or soluble isoform which lacks the transmembrane
domain (sCTLA-4). The expression of both isoforms can
be induced by activated CD4+ T cells and both are
immunosuppressive. Hence, increased cycling of CTLA-4
(e.g. during an AECOPD episode) could reflect increases
in both transmembrane and soluble CTLA-4 because the
commercially available clone of anti-CTLA-4 antibody
(BNI3) used in our study targets both CTLA-4 isoforms.
Future study should investigate the role of sCTLA-4 ver-
sus Tm-CTLA-4 in AECOPD using an anti-CTLA-4 anti-
body clone that specifically targets the sCTLA-4 isoform
(e.g. those generated by Esposito et al.28).
The production of IFN-c was associated inversely with
the proportions of circulating Treg cells and intracellular
CTLA-4+ CD4+ T cells. Furthermore, the production of
IFN-c, TNF-a and IL-6 by PBMC and proportions of
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Figure 1. Proportion of regulatory T (Treg)
cells and cytotoxic T lymphocyte-associated
antigen 4 (CTLA-4)-expressing T cells were
increased in patients with chronic obstructive
pulmonary disease (COPD). Circulating fre-
quency of (a) Treg cells (as % of CD4+ T
cells), (b) intracellular CTLA-4+ Treg cells, (c)
intracellular CTLA-4+ CD4+ T cells, (d) surface
CTLA-4+ Treg cells, (e), surface CTLA-
4+ CD4+ T cells, and (f) surface CTLA-
4+ CD8+ T cells. **P < 001; *P < 005,
Mann-Whitney U-test. The graphs show the
interquartile range (box), median (middle line)
and range (whiskers) for each group.
ª 2017 John Wiley & Sons Ltd, Immunology, 151, 219–226 223
The role of CTLA-4 in COPD
IFN-c- or TNF-a-producing CD4+ and CD8+ T cells from
all subjects (including patients with AECOPD) were
increased by CTLA-4 blockade. Increased production of
IFN-c and TNF-a after CTLA-4 blockade may reflect the
increased proportions of IFN-c- or TNF-a-producing
CD4+ and CD8+ T cells found after CTLA-4 blockade,
even though the expression of CTLA-4 is much lower in
CD8+ T cells compared with CD4+ T cells. As the regula-
tion of T-cell responses by CTLA-4 may be in an intrinsic
or extrinsic manner,16 CTLA-4 blockade may enhance the
activation of CTLA-4+ T cells and neighbouring T cells,
which may have low or no expression of CTLA-4 (e.g.
CD8+ T cells). Furthermore, improvement in CD4+ T-cell
responses upon CTLA-4 blockade may also improve gen-
eral Th1 responses (e.g. increased production in IFN-c),
which may induce the activation of other Th1 cells such
as CD8+ T cells. Hence, increased proportions of CTLA-
4-expressing CD4+ T cells or Treg cells in patients with
COPD may impair Th1 responses needed for clearance of
infections.29,30
Our data support the use of CTLA-4 blockade to
restore Th1 responses (e.g. IFN-c production) in patients
with COPD, which in turn should aid clearance of bac-
terial and/or viral pathogens, so reducing the risk of
AECOPD. The blockade of ‘immune checkpoints’ such
as CTLA-4 has been used to inhibit Treg cell function
and promote effector T-cell responses,31 showing
promising clinical results in anti-tumour treatment.32
Similarly in mice infected with Nippostrongylus brasilien-
sis, Listeria monocytogenes or Mycobacterium bovis,
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Figure 2. Cytotoxic T lymphocyte-associated
antigen 4 (CTLA-4) blockade increased the
production of interferon-c (IFN-c), tumour
necrosis factor-a (TNF-a) and interleukin-6
(IL-6) by peripheral blood mononuclear cells
(PBMC) from patients with an acute exacerba-
tion of COPD (AECOPD) patients, patients
with stable COPD (sCOPD) and controls.
Levels of (a) IFN-c, (b) TNF-a, (c) IL-6 and
(d) IL-10 in cell culture supernatants of anti-
CD3 stimulated PBMC with (right) or without
(left) the addition of anti-CTLA-4 blocking
antibodies. (e) Frequencies of IFN-c- and
TNF-a-producing CD4+ and CD8+ T cells with
CTLA-4 blockade (right) or without CTLA-4
blockade (left) from six participants (two
AECOPD [▼], two sCOPD [▲], two controls
[●]). ***P < 0001; **P < 001; *P < 005,
Wilcoxon matched-pairs signed rank tests.
[Colour figure can be viewed at wileyonline
library.com]
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CTLA-4 blockade enhanced the production of IFN-c and
TNF-a.33–35
Although we had no access to cells from the lung, the
observed increase in proportions of Treg cells matches
that seen in bronchoalveolar lavage and lymphoid follicles
from patients with COPD.23,36 As responses by PBMC
may not reflect respiratory mucosal responses to NTHI,
studies of CTLA-4 expression by T-cells from the lung
and challenge with bacteria implicated in AECOPD epi-
sodes (e.g. NTHI) are warranted to establish CTLA-4
blockade as a viable therapeutic strategy to improve the
production of Th1 cytokines.
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Figure S1. Gating strategies used to identify CTLA-4+
T-cell subsets. (a) Singlets were defined by forward scat-
ter-area (FCS-A) and FCS-Height. (b) Dead cells were
then excluded and (c) lymphocytes were gated based on
side scatter (SSC)-A and FSC-A. (d) CD4+ and (e) CD8+
T cells were identified by co-expression of CD3 with CD4
or CD8, respectively. (f) Co-expression of CTLA-4 and
Foxp3 was assessed in CD4+ T cells.
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